Spyre Therapeutics, Inc.

Spyre Therapeutics reported its second quarter 2026 financial results, including a net loss of $36.2 million, while maintaining a strong cash position of $1.1 billion, providing a runway into the second half of 2029. The company announced positive topline induction data for SPY001 and SPY002 from the SKYLINE trial, demonstrating best-in-class efficacy potential and a consistent safety profile. Enrollment for the SKYWAY basket trial was completed, and Spyre remains on track for six proof-of-concept Phase 2 readouts in 2026, including key data for rheumatoid arthritis, psoriatic arthritis, and axial spondyloarthritis.

Spyre Therapeutics announced its second quarter 2026 financial results and provided program updates. The company reported positive topline induction data for SPY001 and SPY002 from the Phase 2 SKYLINE trial, demonstrating best-in-class efficacy potential and a consistent safety profile. Enrollment for the Phase 2 SKYWAY basket trial is complete, with upcoming data readouts for rheumatoid arthritis in September and psoriatic arthritis/axial spondyloarthritis in Q4 2026. Spyre ended the quarter with $1.1 billion in cash, cash equivalents, and marketable securities, providing a runway into the second half of 2029, while reporting a net loss of $36.2 million.

Spyre Therapeutics, Inc. announced that its Compensation Committee approved the grant of equity inducement awards to six new non-executive employees. These awards include 58,843 stock options and 2,134 restricted stock units (RSUs) under the 2018 Equity Inducement Plan. The grants were material to the employees' acceptance of employment and are subject to specific vesting schedules and continuous service.

Spyre Therapeutics announced positive initial 12-week induction topline data from Part A of its Phase 2 SKYLINE trial for SPY002 in moderately-to-severely active ulcerative colitis. SPY002 met its primary endpoint, demonstrating a statistically significant 10.7-point reduction in the Robarts Histopathology Index (RHI) score. The drug also showed robust rates of clinical remission (33%) and endoscopic improvement (42%), and was well tolerated with a safety profile consistent with its class.

Spyre Therapeutics, Inc. announced that its independent Compensation Committee approved the grant of stock options for an aggregate of 51,300 shares of common stock. These equity inducement awards were granted to four non-executive employees under the Spyre Therapeutics, Inc. 2018 Equity Inducement Plan. The stock options have a 10-year term and an exercise price of $70.54 per share, vesting over a period subject to continuous service.

Spyre Therapeutics announced the completion of enrollment for all sub-studies in its SKYWAY basket trial of SPY072 (anti-TL1A) in rheumatic diseases. The company reiterated its expected Q3 2026 readout for rheumatoid arthritis (RA) and Q4 2026 readouts for psoriatic arthritis (PsA) and axial spondyloarthritis (axSpA). This progress keeps Spyre on track for five of its six planned Phase 2 readouts in 2026 across the SKYWAY and SKYLINE trials. Additionally, preclinical data supporting SPY072 in rheumatic diseases was presented at the 2026 European Congress of Rheumatology (EULAR).

Spyre Therapeutics, Inc. amended its SPY003 License Agreement with Paragon Therapeutics, Inc. on May 29, 2026. The amendment significantly expands the "Field" for SPY003 from solely inflammatory bowel disease to include all therapeutic, prophylactic, palliative, and diagnostic uses. This expansion is subject to certain dosing restrictions, specifically until June 1, 2028, for combination therapies and June 1, 2030, for monotherapies outside inflammatory bowel disease. These restrictions may terminate earlier, by June 1, 2028, upon a material transaction like a change of control.

Spyre Therapeutics, Inc. held its Annual Meeting of Stockholders on May 27, 2026, where several key proposals were approved. Stockholders voted to approve the amended and restated 2016 Employee Stock Purchase Plan and elected three Class I directors: Mark McKenna, Cameron Turtle, and Laurie Stelzer. Additionally, Peter Harwin resigned from the Board, reducing its size to seven directors. Stockholders also approved the compensation of named executive officers on an advisory basis and ratified KPMG LLP as the independent registered public accounting firm.

Spyre Therapeutics announced its management will participate in two upcoming investor conferences. The company will attend the Jefferies Global Healthcare Conference on June 3, 2026, and the Goldman Sachs 47th Annual Global Healthcare Conference on June 8, 2026. Management will also host one-on-one investor meetings, with live webcasts available on the company's investor relations website.

Spyre Therapeutics reported its first quarter 2026 financial results and provided corporate and program updates. The company announced positive topline induction data from Part A of the Phase 2 SKYLINE trial for SPY001, demonstrating best-in-class efficacy potential and a consistent safety profile. Additionally, the RA sub-study of the Phase 2 SKYWAY basket trial was over-enrolled, accelerating its topline readout to the third quarter of 2026. The company reported a net loss of $69.0 million for Q1 2026 and strengthened its balance sheet with $463 million gross proceeds from a public offering, resulting in $1.2 billion in pro forma cash with a runway into the second half of 2029.